Welcome to our dedicated page for Alector SEC filings (Ticker: ALEC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Alector, Inc. filings document a Nasdaq-listed biotechnology issuer developing therapies for neurodegenerative diseases and reporting progress across the Alector Brain Carrier (ABC) platform. Its 8-K reports include operating and financial results, clinical and portfolio updates, material agreements, and officer appointments.
Regulatory documents also cover the company’s common stock, shelf registration statement and at-the-market equity sales agreement, along with governance matters in proxy materials such as board elections, executive compensation and shareholder voting items. Clinical disclosures address programs in Alzheimer’s disease, Parkinson’s disease, frontotemporal dementia and related neurological disorders, while event filings frame capital resources, platform development, trial outcomes and pipeline changes.
Alector, Inc. (ALEC) announced a major restructuring tied to outcomes from its Phase 3 INFRONT-3 trial of latozinemab (AL001) in FTD-GRN. The company will reduce its workforce by approximately 49%, affecting about 75 employees, and will discontinue the open-label extension portion of INFRONT-3 as well as the continuation study for latozinemab.
Total incremental restructuring charges are expected to be about $7.7 million, primarily for severance and related termination benefits. Cash payments are expected to be paid out and the reduction in force completed during the first half of 2026. The company noted these estimates are subject to assumptions and may change.
Leadership update: Sara Kenkare-Mitra, Ph.D., President and Head of R&D, will resign effective December 22, 2025. Under a separation agreement, she will receive a lump-sum equal to nine months of base salary, a payment equal to 50% of her annual bonus target, and nine months of company-paid COBRA premiums. Alector also issued a press release with INFRONT-3 data results that included a preliminary estimate of cash, cash equivalents, and short-term investments as of September 30, 2025.
Alector, Inc. (ALEC) Form 4 by Grace Wong-Sarad reports a routine disposition of company common stock tied to RSU vesting tax obligations. The reporting person sold a total of 5,910 shares on 09/02/2025 at a weighted-average price of $2.4968, with individual trade prices ranging from $2.30 to $2.59. After the sale, the reporting person beneficially owns 103,448 shares. The filing states the shares were sold to satisfy tax obligations arising from the vesting of restricted stock units.
Alector, Inc. (ALEC) director and Principal Financial Officer Neil Lindsay reported a sale of 15,842 shares of common stock on 09/02/2025. The sale was executed at a weighted-average price of $2.4968 per share, with individual trade prices ranging from $2.30 to $2.59. According to the filing, the shares were sold to satisfy tax obligations arising from the vesting of restricted stock units. After the reported transactions, the reporting person beneficially owned 346,570 shares directly. The Form 4 was signed by Grace Wong-Sarad by power of attorney on 09/04/2025.
Sara Kenkare-Mitra, President and Head of R&D of Alector, Inc. (ALEC), reported a sale of common stock tied to RSU vesting. On 09/02/2025 she disposed of 23,638 shares at a weighted average price of $2.4968 per share; the filing explains the sale satisfied her tax obligations from vested restricted stock units. Following the reported transaction she beneficially owned 543,339 shares. The Form 4 was signed by Grace Wong-Sarad by power of attorney on 09/04/2025. The filing provides the price range for the multiple sale transactions as $2.30 to $2.59 and offers to furnish detailed per-transaction quantities on request.
Arnon Rosenthal, who serves as Chief Executive Officer and a director of Alector, Inc. (ALEC), reported a sale of 51,562 shares of common stock on 09/02/2025 at a weighted average price of $2.4968 per share to satisfy tax obligations arising from the vesting of restricted stock units (RSUs). After the reported sale, the filing shows 2,350,220 shares directly beneficially owned by the reporting person. Additional indirect holdings are disclosed across family trusts totaling 3,930,375 shares (1,972,875; 652,500; 652,500; 652,500). The filing also states that 150,000 performance share units (PSUs) were forfeited on May 6, 2025 because performance metrics were not achieved.
Alector, Inc. (ALEC) filing of Form 144 reports an intended sale of 15,426 shares of common stock through Morgan Stanley Smith Barney LLC with an aggregate market value of $36,251.10. The filing shows approximately 101,212,329 shares outstanding and lists an approximate sale date of 09/02/2025.
The securities were acquired on 08/29/2025 by vesting of restricted stock units (30378 units originally noted) with payment dated 08/29/2025. The filer also disclosed a prior sale: 11,158 shares sold on 06/02/2025 for gross proceeds of $14,933.87. The notice contains the standard representation that the seller is not aware of undisclosed material adverse information.
Alector, Inc. insider sale notice: The filing reports that 50,242 shares of Alector common stock will be offered for sale via Morgan Stanley Smith Barney, with an aggregate market value of $118,068.70 and an approximate sale date of 09/02/2025. The shares were acquired on 08/29/2025 upon vesting of restricted stock units totaling 98,939 shares; payment was recorded on the same date. The company has 101,212,329 shares outstanding, so the planned sale represents about 0.05% of outstanding shares. The filer also reported a prior sale on 06/02/2025 of 52,087 shares for $69,713.24. The notice includes the required representation that the seller is not aware of undisclosed material adverse information.
Alector, Inc. (ALEC) Form 144 shows a proposed sale of 5,717 shares of common stock through Morgan Stanley Smith Barney on 09/02/2025 with an aggregate market value of $13,434.95. The shares were acquired by vesting of restricted stock units on 08/29/2025 totaling 11,257 units, with payment/settlement dated 08/29/2025. The filer previously sold 6,034 shares on 06/02/2025 for gross proceeds of $8,075.91. The filing includes the standard representation that the seller is not aware of undisclosed material adverse information about the issuer.
Alector, Inc. (ALEC) Form 144 notice shows that 23,019 shares of Common Stock (aggregate market value $54,094.65) are proposed to be sold through Morgan Stanley Smith Barney on 09/02/2025 on Nasdaq. The shares were acquired on 08/29/2025 by vesting of restricted stock units from the issuer, with 45,330 RSU units recorded as acquired that date. The filing also discloses a prior sale by the same person: 23,890 shares sold on 06/02/2025 for $31,974.38. The notice includes the standard representation that the seller is not aware of any undisclosed material adverse information about the issuer.
Paula Hammond, a director of Alector, Inc. (ALEC), reported a planned sale of common stock executed on 08/26/2025 under a Rule 10b5-1 trading plan adopted on May 27, 2025. The filing shows 14,000 shares were sold at a weighted average price of $2.357, with individual trade prices ranging from $2.31 to $2.385. After the reported sales, Hammond beneficially owned 74,909 shares directly. The Form 4 was submitted by one reporting person and signed by Grace Wong-Sarad by power of attorney on 08/27/2025. All details in this summary are taken directly from the Form 4 provided.